Article

A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder

The Krembil Family Epigenetics Laboratory, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Molecular Psychiatry (Impact Factor: 15.15). 06/2011; 17(7):728-40. DOI: 10.1038/mp.2011.64
Source: PubMed

ABSTRACT Epigenetic studies of DNA and histone modifications represent a new and important activity in molecular investigations of human disease. Our previous epigenome-wide scan identified numerous DNA methylation differences in post-mortem brain samples from individuals affected with major psychosis. In this article, we present the results of fine mapping DNA methylation differences at the human leukocyte antigen (HLA) complex group 9 gene (HCG9) in bipolar disorder (BPD). Sodium bisulfite conversion coupled with pyrosequencing was used to interrogate 28 CpGs spanning ∼700 bp region of HCG9 in 1402 DNA samples from post-mortem brains, peripheral blood cells and germline (sperm) of bipolar disease patients and controls. The analysis of nearly 40 000 CpGs revealed complex relationships between DNA methylation and age, medication as well as DNA sequence variation (rs1128306). Two brain tissue cohorts exhibited lower DNA methylation in bipolar disease patients compared with controls at an extended HCG9 region (P=0.026). Logistic regression modeling of BPD as a function of rs1128306 genotype, age and DNA methylation uncovered an independent effect of DNA methylation in white blood cells (odds ratio (OR)=1.08, P=0.0077) and the overall sample (OR=1.24, P=0.0011). Receiver operating characteristic curve A prime statistics estimated a 69-72% probability of correct BPD prediction from a case vs control pool. Finally, sperm DNA demonstrated a significant association (P=0.018) with BPD at one of the regions demonstrating epigenetic changes in the post-mortem brain and peripheral blood samples. The consistent multi-tissue epigenetic differences at HCG9 argue for a causal association with BPD.

Download full-text

Full-text

Available from: Ilya Ioshikhes, May 01, 2014
0 Followers
 · 
235 Views
 · 
38 Downloads
  • Source
    • "In the human genome, 5hmC is highly enriched on exons and untranslated regions, but depleted on introns and intergenic regions (Wang et al., 2012). In addition, fetus-specific and adult-specific differentially hydroxymethylated regions in exons and CpG islands have been identified (Kaminsky et al., 2012). In the adult brain, 5hmC has been implicated in the regulation of activity-dependent plasticity and gene expression critical for consolidation of memory. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adaptation to environmental changes is based on the perpetual generation of new phenotypes. Modern biology has focused on the role of epigenetic mechanisms in facilitating the adaptation of organisms to changing environments through alterations in gene expression. Inherited and/or acquired epigenetic factors are relatively stable and have regulatory roles in numerous genomic activities that translate into phenotypic outcomes. Evidence that dietary and pharmacological interventions have the potential to reverse environment-induced modification of epigenetic states (e.g., early life experience, nutrition, medication, infection) has provided an additional stimulus for understanding the biological basis of individual differences in cognitive abilities and disorders of the brain. It has been suggested that accurate quantification of the relative contribution of heritable genetic and epigenetic variation is essential for understanding phenotypic divergence and adaptation in changing environments, a process requiring stable modulation of gene expression. The main challenge for epigenetics in psychology and psychiatry is to determine how experiences and environmental cues, including the nature of our nurture, influence the expression of neuronal genes to produce long-term individual differences in behavior, cognition, personality, and mental health. To this end, focusing on DNA and histone modifications and their initiators, mediators and readers may provide new inroads for understanding the molecular basis of phenotypic plasticity and disorders of the brain. In this chapter, we review recent discoveries highlighting epigenetic aspects of normal brain development and mental illness, as well as discuss some future directions in the field of behavioral epigenetics.
    Advances in genetics 01/2014; 86C:277-307. DOI:10.1016/B978-0-12-800222-3.00011-5 · 5.41 Impact Factor
  • Source
    • "One area of genetic research that may in the future prove to be useful in classification of treatment and nontreatment responders will be the examination of methylation status of genomic DNA. This approach has been tried in peripheral samples in BD and SZ for demonstrating differences in methylation levels of single genes and genomewide between affected individuals and controls [7] [8] [9] [10], while in MDD, a majority of methylation studies have been performed in postmortem brain [11] [12]. In MDD, there have also been studies investigating the association of methylation and histone modifications with antidepressant treatment response (reviewed in [13]). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mood disorders and schizophrenia are common and complex disorders with consistent evidence of genetic and environmental influences on predisposition. It is generally believed that the consequences of disease, gene expression, and allelic heterogeneity may be partly the explanation for the variability observed in treatment response. Correspondingly, while effective treatments are available for some patients, approximately half of the patients fail to respond to current neuropsychiatric treatments. A number of peripheral gene expression studies have been conducted to understand these brain-based disorders and mechanisms of treatment response with the aim of identifying suitable biomarkers and perhaps subgroups of patients based upon molecular fingerprint. In this review, we summarize the results from blood-derived gene expression studies implemented with the aim of discovering biomarkers for treatment response and classification of disorders. We include data from a biomarker study conducted in first-episode subjects with schizophrenia, where the results provide insight into possible individual biological differences that predict antipsychotic response. It is concluded that, while peripheral studies of expression are generating valuable results in pathways involving immune regulation and response, larger studies are required which hopefully will lead to robust biomarkers for treatment response and perhaps underlying variations relevant to these complex disorders.
    Disease markers 07/2013; 35(1):11-21. DOI:10.1155/2013/748095 · 2.17 Impact Factor
  • Source
    • "ST6GALNAC1 encodes α-N-acetylgalactosaminide α-2,6-sialyltransferase 1, an enzyme that transfers sialic acid to O-linked N-acetylgalactosamine residues, but its function has not been fully elucidated. Similarly, studies of bipolar disorder also demonstrated that methylation status at specific CpG sites in SLC6A4 (which encodes a serotonin transporter, one of the main targets of antidepressants) and human leukocyte antigen complex group 9 gene (HCG9, which is located within the MHC class I region) showed a common pattern in brain and blood samples [63,64]. More recently, Davies et al. [65] also reported that DNA methylation differences in blood samples and those in postmortem brain samples were well correlated in the investigated genomic regions, indicating the utility of peripheral tissue samples in studying mental disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a severe psychiatric disease affecting about 1% of the world's population, with significant effects on patients and society. Genetic studies have identified several candidate risk genes or genomic regions for schizophrenia, and epidemiological studies have revealed several environmental risk factors. However, the etiology of schizophrenia still remains largely unknown. Epigenetic mechanisms such as DNA methylation and histone modifications can explain the interaction between genetic and environmental factors at the molecular level, and accumulating evidence suggests that such epigenetic alterations are involved in the pathophysiology of schizophrenia. However, replication studies to validate previous findings and investigations of the causality of epigenetic alterations in schizophrenia are needed. Here, we review epigenetic studies of schizophrenia patients using postmortem brains or peripheral tissues, focusing mainly on DNA methylation. We also highlight the recent progress and challenges in characterizing the potentially complex and dynamic patterns of epigenomic variations. Such studies are expected to contribute to our understanding of schizophrenia etiology and should provide novel opportunities for the development of therapeutic drugs.
    Genome Medicine 12/2012; 4(12):96. DOI:10.1186/gm397 · 4.94 Impact Factor
Show more